CCRD ‘very confident’ it will be approved by the U.S. Food and Drug Administration (FDA)

CCRDF President Tom Sjostrom announced the agency's approval of the company's second and third drug therapies for the chronic wasting disease, Chronic Traumatic Encephalopathy (CTE).The approval is a result of a review of the drugs' clinical trial data, a decision made by the agency last year after CCRDP submitted additional evidence of effectiveness.CCRDEP is in the process of evaluating CTE trea...